Ms. Wu is skilled in patent application drafting, office action responses, reexamination, invalidation, administrative litigation, patent due diligence and freedom-to-operate investigation, patent analysis and other services. She has accumulated rich patent legal service experience in the fields of pharmacy, life sciences, chemistry, materials science and other technologies. In addition to handling Chinese patent applications, Ms. Wu also has the qualification to handle US patent applications. Ms. Wu also cooperates with local lawyers to complete patent agency services in Europe, Canada, Australia, India, Brazil and other countries and regions in the patent application granting procedure.

Ms. Wu has rich experience in Chinese and English drafting. She was selected as one of the first batch of high-level talents in the patent agency industry (patent document drafting type) by the All-China Agents Association in 2013. The international application PCT/CN2014/091138 she drafted was included in the “National Excellent Invention Patent Application Agency Case Selection (2016)”. The invention patent invalidation case (invention name: “Phenylpiperazine derivatives as serotonin reuptake inhibitors”) represented by Ms. Wu was selected as one of the top ten cases of patent reexamination and invalidation by the China National Intellectual Property Administration in 2022.

Ms. Wu joined Lung Tin in 2002. She was licensed to practice as a Chinese Patent Attorney in 2005, and was designated as a litigation patent attorney by the Supreme People’s Court in 2013, and obtained the qualification of US patent attorney in 2019.

Lung Tin Intellectual Property Agent LTD., Partner, Manager, Senior Patent Attorney
Institue of Materia Medica Chinese Academy of Medical Science, in Drug synthesis research

M.S., Beijing Union Medical College, in Medical Chemistry
B.S., Inner Mongolia Medical University, in Pharmaceutical Science
Center for International Intellectual Property Studies (CEIPI) in Strasbourg (France), IP Law training program.
The John Marshall Law School (U.S.) , IP Law training program
China University of Political Science and Law , in Intellectual Property Law.

Author, "Res Judicata: Applicable Doctrine in Chinese Patent Invalidation Procedures", China Intellectual Property Magazine, 2020
Author, “Can Commercial Success Be a Central Factor of the Test for Inventiveness”, Attorney’ s Perspectives On IP Practice, Issue No. 3, 2018
Author, “Comparison of Examination Practice in respect of contrary public interest among CN, EP and US”, Patent Agency, Issue No. 3, 2017
Author, “Assessing Novelty in China—Do Prior Art References Need to Be Enabling”, China Intellectual Property, Issue No. 125, July 2017
Author, “Diagnostic patenting: where does China stand?”, China: Managing the IP Lifecycle 2016/2017, IAM, World Trademark Review
Author, “Claim Definitions Undergoing Change”, INTELLECTUAL PROPERTY FOCUS-China 2014
Author, “The Importance of Thorough Searches in Proving Inventiveness”, INTELLECTUAL PROPERTY FOCUS-China 2013
Author, “It Is Good Time for Changing the Principle for Examining Applications in Biotech Field”, Theory and Practice of Paragraph 4 of Article 26 of the Patent Law - Selection of Papers for High-Level Seminar on Patent Examination and Patent Agent in 2012

One of the highest-level attorneys at patent drafting, All China Patent Agent Association (ACPAA)
"Zhongguancun Foreign Intellectual Property Service Expert", Zhongguancun Intellectual Property Promotion Office
Expert, National Intellectual Property Expert Database